Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease

ABSTRACT Background Impulsivity and dopamine dysregulation syndrome are frequent complications of treatment in Parkinson's disease (PD). Methods We assessed the effect of jejunal levodopa infusion (JLI) on behavioral symptoms in 8 PD patients with motor complications and severe impulsivity and...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders Vol. 28; no. 14; pp. 2007 - 2010
Main Authors: Catalán, María José, de Pablo-Fernández, Eduardo, Villanueva, Clara, Fernández-Diez, Servando, Lapeña-Montero, Teresa, García-Ramos, Rocío, López-Valdés, Eva
Format: Journal Article
Language:English
Published: United States Blackwell Publishing Ltd 01-12-2013
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Background Impulsivity and dopamine dysregulation syndrome are frequent complications of treatment in Parkinson's disease (PD). Methods We assessed the effect of jejunal levodopa infusion (JLI) on behavioral symptoms in 8 PD patients with motor complications and severe impulsivity and dopamine dysregulation syndrome (DDS), which had not be controlled before by adjusting oral medications. The infusion was delivered during 15 hours (daily dose 1007.2 ± 302.5 mg) and stopped at night time. Patients were reassessed after 25 ± 9 weeks of treatment with a stable dose of jejunal l‐dopa. Results Off periods and dyskinesias decreased by 27% and 20,7% respectively, compared to baseline. DDS and all types of impulse control disorders (ICDs) improved in all patients, with nearly complete symptom resolution. Punding improved in all 5 patients but disappeared completely in only 1. Conclusions Our experience suggests that l‐dopa infusion has a positive effect on both motor complications and behavioral disorders. This treatment approach deserves further controlled studies. © 2013 International Parkinson and Movement Disorder Society
Bibliography:ark:/67375/WNG-8JJDV6D9-S
ArticleID:MDS25636
istex:A84AEA35A0CD1C5E00ADF722F205130AB91C0B36
Full financial disclosures and author roles may be found in the online version of this article.
Nothing to report.
Relevant conflicts of interest/financial disclosures
Funding agencies
This study was partially supported by a grant from Ministerio de Ciencia e Innovación, Instituto Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED INTCBN 09/203), Madrid, Spain.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.25636